
Great job @MunozEspin_Lab and colleagues, eager to hear it at IRCM and @ICM_Montpellier at your visit in June!
✓Antonio Maraver, PhD, is Head of “Oncogenic pathways in lung cancer” lab at Montpellier Cancer Research Institute (IRCM)

Great job @MunozEspin_Lab and colleagues, eager to hear it at IRCM and @ICM_Montpellier at your visit in June!

Senescence links regeneration to oncogenic vulnerability. Our latest work demonstrates that senescence drives postpartum mammary involution while simultaneously creating a transient microenvironment permissive for tumor initiation. #senescence, #postpartum, #breastcancer

Tiens, ça faisait longtemps que je n’étais pas allé sur le site de @PhilipMorris_FR . Jamais déçu par cette communication cynique. Vous n’oubliez pas dans votre synthèse l’empreinte sur la santé de vos produits et les millions de morts ? 🤔

Indeed!!! Terrific session with great science and fantastic colleagues to share the stage

Thanks to the #WCLC25 @IASLC for the opportunity to give a talk alongside and amazing lineup of speakers and chairs @MaraverLab @triparnasen #carolinedive @HaradaGuilherme @AyaHelali

Therapeutic oligonucleotides are gaining ground in oncology. They offer a new way to target cancer at the genetic level — with precision and flexibility that traditional drugs often can’t match. Watch this video to learn more▶️ #oncology #RNAtherapeutics #biotech #TAONASLUAD

🔗 COALA project website is now live! 👉 coala-lung.org A national multidisciplinary consortium supported by the @Institut_cancer bringing together experts in lung cancer research to improve outcome of lung cancer patients with oncogenic addiction.

Look at this interesting work from @MaraverLab! FMO as a novel target for lung cancer. Congrats to the whole team! 👇🏻👇🏻

This work was possible thanks to a fantastic and complementary group of colleagues from @IRCM_MTP @ICM_Montpellier @umontpellier @goteborgsuni @CNIOStopCancer @CIMA_unav @H12Octubre @nyulangone Thanks a lot to all our great collaborators!! Together we are stronger!!!

As you know, ferroptosis inhibitors are still far from being used in the clinic, but our findings provide a new way to sensitize cells against them which could facilitate their clinical translation, at least to treat the leading cause of death by cancer in the world, i.e., lung.

4. We further dissect the mechanism and uncovered that FMO4 binds MAT2A, leading to the stabilization of the MAT2A-MAT2B complex in order to promote the generation of cysteine that in turn regenerates reduced glutathione to allow GPX4-driven protection against ferroptosis.

2. We demonstrate that FMO is critically required for KRAS-driven lung cancer generation and maintenance in mice in vivo. 3. We found that FMO4 deletion in lung cancer sensitizes cells against ferroptosis both in vitro and in vivo, revealing FMO4 as an interesting cancer target.

1. We first found that flavin containing monooxygenase 4 (FMO4) is highly expressed in lung tumors and very low expressed in healthy lung in mouse and lung cancer patients where its expression negatively correlates with patients’ survival.

Thrilled to present our study aiming to identify new vulnerabilities in lung cancer: biorxiv.org/content/10.1101/… Joining forces from mouse genetics, thoracic oncology, metabolism, and AlphaFold fields we dissected the role of a largely unknown but essential protein in cancer, FMO4 🧵


Terrific start and eager to move on, together we are stronger 💪🏽thanks a lot @JulienMazieres for federating this great adventure